The voltage-gated sodium channel Na\textsubscript{v}1.7 associated with endometrial cancer

Junxiu Liu\textsuperscript{1*}, Hao Tan\textsuperscript{1*}, Wancai Yang\textsuperscript{2}, Shuzhong Yao\textsuperscript{1,2*}, Liang Hong\textsuperscript{2*}

\textsuperscript{1}Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
\textsuperscript{2}Institute of Precision Medicine, Jining Medical University, Jining, China.

*These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2018.11.15; Accepted: 2019.06.25; Published: 2019.08.27

Abstract

**Background:** Endometrial cancer is the most common gynecologic malignancy in women in the developed countries. Despite recent progress in functional characterization of voltage-gated sodium channel (Na\textsubscript{v}) in multiple cancers, very little was known about the expression of Na\textsubscript{v} in human endometrial cancer. The present study sought to determine the role of Na\textsubscript{v} and molecular nature of this channel in the endometrial cancer.

**Methods:** PCR approach was introduced to determine expression level of Na\textsubscript{v} subunits in endometrial cancer specimens. Pharmacological agents were used to investigate Na\textsubscript{v} function in endometrial cancer cells. Flow cytometry were used to test cancer apoptosis, and invasion assays were applied to test tumor metastasis.

**Results:** Transcriptional levels of the all Na\textsubscript{v} α and β subunits were determined by real time-PCR in endometrial cancer with pair tissues of carcinoma and adjacent nonneoplastic tissue, Na\textsubscript{v}1.7 was the most highly expressed Na\textsubscript{v} subtype in endometrial cancer tissues. Na\textsubscript{v}1.7 level was closely associated with tumor size, local lymph node metastasis, and 5-year and 10-year survival ratio. Inhibition of this channel by Na\textsubscript{v}1.7 blocker PF-05089771, promoted cancer apoptosis and attenuated cancer cell invasion.

**Conclusion:** These results establish a relationship between voltage-gated sodium channel protein and endometrial cancer, and suggest that Na\textsubscript{v}1.7 is a potential prognostic biomarker and could serve as a novel therapeutic target for endometrial cancer.

Key words: Endometrial Cancer; Na\textsubscript{v}1.7; Voltage-Gated Sodium Channel; Ion Channels.

Introduction

Endometrial cancer is a major cause of morbidity for women worldwide, and approximately 3% of women develop endometrial cancer at some point during their lifetimes [1]. The 5-year survival rate for women with stage I endometrial cancer is 90%, it drops to 57% in patients with stage III, and to 20% in patients with stage IV [2]. As the determinant of survival in endometrial cancer is the stage of disease at diagnosis, the early detection and effective therapy are of considerable importance. Recently, ion channels have emerged as new biomarkers for human cancers, and some have been shown to correlate with the main hallmarks of the cancer process and serve as pharmacological targets in the cancer chemotherapy [3].

The voltage-gated sodium channels (Na\textsubscript{vs}) are responsible for the fast action potentials involved in nerve and cardiac conduction [4], they were recently found to play crucial roles in cancer development and progression [5]. The family of sodium channels has...
nine members named Na,1.1 through Na,1.9. Among them, the Na,1.5 has been shown to be associated with colon cancer and breast cancer metastasis [6, 7]; inhibition of Na,1.6 reduced invasiveness of cervical cancer primary culture cells [8]; and in prostate cancer, Na,1.8 expression was revealed to be closely correlated with pathologic stage of cancer specimens [9]. Despite recent progress in the functional characterization of sodium channel in multiple cancers, very little was known about the expression of Na, in human endometrial cancer; furthermore, the molecular basis of sodium channel in this type of cancer has not yet been identified.

In this study, we used primary cultures to investigate the potential role of Na, in endometrial cancer. The present study aimed to determine whether voltage-gated sodium channel protein functionally expressed in the endometrial cancer with metastatic potential, whether their expressions are associated with clinical outcome, and what molecular nature of sodium channels are in the endometrial cancer, whether their activities contribute cellular behaviors integral to metastasis.

Materials and Methods

Patients and tissue samples

A total of 80 surgical specimens of endometrial cancer tissues were collected from patients at the Department of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-Sen University from 2006 to 2016 without prior radiotherapy or chemotherapy. Twenty paired surgical tumor and normal adjacent tissues were obtained with the patients’ consent from the patients registered at the First Affiliated Hospital. The normal adjacent tissue, defined as histologically benign-appearing tissue and judged by an experienced pathologist, is acquired from the margins of the tumor resection. A separate set of frozen tumor specimens for Kaplan-Meier analyses were obtained from sixty patients. The Na,1.7 expression determined by quantitative PCR was evaluated in those specimens, MRPL19 was used as the reference gene to normalize Na,1.7 expression, the group Na,1.7-High or Na,1.7-Low were defined as scores above or below the median. The study was approved by the Institutional Review Board of First Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Patient studies were conducted in accordance with ethical guideline of Declaration of Helsinki.

Cell culture

Fresh endometrial cancer biopsies were digested with collagenase (1 mg/ml; Sigma-Aldrich) in Hanks Balanced Salt solution (HBSS) at 37°C for 30 min. The suspended cells were collected by centrifugation at 500 r.p.m for 5 min at 4°C, cells were transferred to a fresh tube containing HBSS, washed and centrifuged again. Then the primary cells were plated on coverslips in Falcon polystyrene microplates 6-well plates, and maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) with 10% fetal bovine serum (FBS, Gibco), 100 U/ml penicillin and 100U/ml streptomycin (Invitrogen) in a 37°C incubator with 5% CO2 [10, 11].

RNA isolation and cDNA synthesis

Total RNA was extracted from endometrial cancer and nonneoplastic endometrial tissues using TRizol RNA extraction agent (Invitrogen) according to the manufacturer’s instructions [12]. Only RNA that resulted in an A260/280 ratio of 1.8-2.0 was reverse transcribed to generate cDNA. Synthesis of cDNA was carried out with SuperScript II RNase Reverse Transcriptase (Invitrogen) and primers (Invitrogen) at 42°C with 2µg of total RNA as template, in a final volume of 20µl. Negative controls for the reverse-transcription reaction were prepared by omitting the RT enzyme [13, 14]. For the reverse transcription-PCR, the relative intensity of Na,1.7 mRNA expression was measured by densitometry (ImageJ, Bethesda, USA). For conventional end-point PCR, 100 ng of cDNA was amplified following addition to a 30µl mastermix containing dNTPs, Platinum Taq DNA polymerase (Invitrogen) enzyme and appropriate forward and reverse primers for the desired Na, α subunits target gene. Amplicons were visualized under UV light following separation through a 1% agarose gel containing ethidium bromide.

Quantitative real time-PCR

Quantitation of Na, α and β subunits and MRPL19 mRNA was carried out by real time PCR using SYBR I green chemistry on an MJ Chromo 4 thermal cycler (BioRad, USA) [15-17]. Approximately 1 ng/µl of cDNA was added to Platinum SYBR Green qPCR Supermix-UDG (Invitrogen) and primers in a 25µl reaction. Standard curves were generated from serially diluted endometrial cDNA and the Na, subunits transcripts quantitated by normalizing expression relative to the reference gene MRPL19. The CT (threshold cycle) value was determined in each experimental group. The data normalization was performed by using the CT value from human MRPL19 (ΔCT=CTMRPL19-CT reference) as the ΔCT for EC samples was then normalized to NE samples (ΔΔCT=ΔCTEC-ΔCTNE), the ΔΔCT was converted to -2ΔΔCT to calculate the relative expression levels of Na, α and β subunits [8]. The primer pairs used for polymerase chain reaction for all Na, α and β subunits and MRPL19 were shown in the Table 1.
Flow cytometry analysis

The annexin V-fluorescence isothiocyanate (FITC)/PI apoptosis detection kit (BD Biosciences) was used to assess apoptosis. After 48 hours’ drug incubation, the cells from each sample (1×10⁶) were re-suspended in 200μl of staining buffer and mixed with 10μl of annexin V-FITC for 15 min. After adding 200μl staining buffer and 10μl PI, flow cytometry was performed to analyze the percentage of apoptotic cells [18, 19].

Invasion assays

The endometrial cancer cells (1×10⁶) were seeded in the top well of a Matrigel-coated invasion chamber (BD Biosciences) in DMEM containing 0.1% FBS with or without pharmacological agents (Tetrodotoxin, veratridine or PF-05089771). The bottom well was filled with 750μl DMEM containing 10% FBS as a chemoattractant. After 6-48 hour, non-invading cells were scraped from the upper side of the insert using a cotton swab. Invading cells on the bottom of the insert were fixed and stained with Diff-Quick Stain (IMEB cotton swab). Invading cells on the bottom of the insert were scraped from the upper side of the insert using a cotton swab. Invading cells on the bottom of the insert were fixed and stained with Diff-Quick Stain (IMEB cotton swab). Invading cells on the bottom of the insert were scraped from the upper side of the insert using a cotton swab. Invading cells on the bottom of the insert were fixed and stained with Diff-Quick Stain (IMEB cotton swab).

Data analysis

All data are presented as the means ± standard error of the mean. The n value denotes the number of independent experiments conducted. Significance between means was determined using either the two-tailed Student's paired t-test or one-way analysis of variance with Dunnett’s multiple comparisons test. Kaplan-Meier and log rank tests were used to assess differences in overall survival or disease-specific survival by Na v1.7-High vs Na v1.7-Low. P<0.05 was considered to indicate a statistically significant difference.

Results

Expression levels of Na v α subunits in endometrial cancer and nonneoplastic endometrial samples.

The voltage-gated sodium channel (Nav) has been shown to play important roles in cancer development and progression [5]; however, it has not been known whether Na v expression level has relationships with endometrial tumor malignancy. To test this possibility, we examined the mRNA expression level of Nav in endometrial cancer specimens. Transcriptional levels of the all Nav α and β subunits were determined by real time-PCR in the six cases of endometrial cancer with pair tissues of carcinoma (EC) and adjacent nonneoplastic tissue (NE), the mitochondrial ribosomal protein L19 (MRPL19) was introduced as the reference gene to normalize Nav subtype gene expression [23]. The cycle threshold values were plotted to compare gene expression, and the real time-PCR analyses revealed that Nav1.7 was the most highly expressed Na v subtype in the tissues (Fig. 1), and relative mRNA expression of Na v1.7 in EC biopsies were approximately 25-fold higher than in NE samples (Fig. 1c), indicating that overexpression of Na v1.7 was associated with endometrial tumorigenesis.

Nav1.7 expression was associated with endometrial cancer metastasis and clinical outcome.

To investigate if Na v1.7 expression has clinical significance in tumor progression in endometrial cancer, we analyzed 20 sets of endometrial cancers with pair tissues of EC and adjacent NE tissue, and found that 75% cases (15 of 20 endometrial cancer) expressed significantly elevated level of Na v1.7 expression compared with paired adjacent normal tissue (Fig. 2a-b). Nav1.7 expression was downregulated in 4 cases, one possible reason is due
to heterogeneity or individual difference in patients. More importantly, the Na\textsubscript{v}1.7 expression level was closely correlated with tumor size (Fig. 2c), a crucial indicator for the state of disease progression in human endometrial cancer [24]. In addition, the level of Na\textsubscript{v}1.7 expression in tumor tissues was significantly higher in the group of local lymph node metastasis (Fig. 2d).

We further determined the association between tumor expression of Na\textsubscript{v}1.7 and clinical outcome of patients with endometrial cancer (Fig. 3a), and observed that patients with high-level tumor expression of Na\textsubscript{v}1.7 exhibited a shorter 5-year and 10-year survival ratio as compared with the Na\textsubscript{v}1.7-low group (38\% vs 81\% and 19\% vs 62\%, respectively) (Fig. 3b-c).

**Nav1.7 involved in endometrial cancer apoptosis**

We next asked whether Na\textsubscript{v}1.7 activities contribute to the development of endometrial cancer, we tested effects of veratridine and PF-05089771 on endometrial cancer cells. Veratridine is a Na\textsubscript{v}1.7 activator [25], it was able to induce persistent Nav1.7 currents [26], and inhibited channel inactivation and generated enhanced window currents. PF-05089771 was previously identified as a state-dependent Na\textsubscript{v}1.7 specific inhibitor interacting with Na\textsubscript{v}1.7 voltage-sensor domain of domain IV [27, 28]. We used flow cytometry analysis to investigate the consequences of veratridine and PF-05089771 on the cancer cell apoptosis. The cells were divided into three groups as shown in Suppl. Fig. 1a-c. The results showed that PF-05089771 were able to increase the number of early and late apoptotic cells, whereas veratridine reduced late apoptosis (Suppl. Fig. 1d), indicating that the Na\textsubscript{v}1.7 may have a critical role in endometrial cancer development.

**Endometrial cancer invasion is mediated by Na\textsubscript{v}1.7.**

To determine whether Na\textsubscript{v}1.7 sodium channel participates in metastatic cell behaviors, the invasion assays were performed with endometrial cancer cells. The role of sodium channel in EC cells was assessed using the specific blocker Tetrodotoxin (TTX). The results revealed that TTX attenuated the relative invasiveness of EC cells. As shown in Fig. 4, the treatment with 10 \mu M TTX for 24 hours significantly decreased the number of invading cells. We then introduced veratridine and PF-05089771 to test roles of Na\textsubscript{v}1.7 in EC. The results revealed that 100\mu M veratridine increased invasion over 48-hour time period compared to control (Fig. 5). On the contrary, PF-05089771 significantly attenuated the relative invasiveness of EC cells, treatment with 100\mu M PF-05089771 remarkably reduced number of invading cells (Fig. 5). These results, together with the data that patients with local lymph node metastasis have

---

**Fig. 1.** Expression levels of Na\textsubscript{v} subunits in endometrial cancer with paired tissues of carcinoma (EC) and adjacent nonneoplastic tissue (NE). a-b Mean cycle threshold value of Na\textsubscript{v} \alpha\ subunits (a), Na\textsubscript{v} \beta\ subunits (b), and housekeeping gene MRP19 in primary EC biopsies (black boxes, n=6) and NE samples (white boxes, n=6). c-d Real-time quantitative PCR of Na\textsubscript{v} \alpha\ (c) and \beta\ subunits (d) mRNA levels fold changes in EC and NE samples, bars showed the average fold-change ratios of Na\textsubscript{v} \alpha\ or \beta\ subunits gene expression levels between EC and NE tissues for the indicated Na\textsubscript{v} subunits. MRP19 was used as the reference gene to normalize Na\textsubscript{v} subunits gene expression (n=6, *p<0.05).
higher level of Na\textsubscript{v}1.7 expressions (Fig. 2d), showed that the Na\textsubscript{v}1.7 plays a critical role in EC metastatic behaviors. And the effects of veratridine on cancer cell invasion were due to enhancement of Na\textsubscript{v}1.7 activities, whereas blockade of Na\textsubscript{v}1.7 by PF-05089771, attenuated endometrial cancer cell invasion.

Fig. 2. Na\textsubscript{v}1.7 expressions associated with endometrial cancer metastasis and clinical outcome. a Na\textsubscript{v}1.7 expressions were determined in EC and NE tissues from 20 endometrial cancer patients. N and T, nonneoplastic endometrial tissues, and tumor areas of the same endometrial cancer patients, respectively. b Na\textsubscript{v}1.7 expression level in tumor biopsies. Navel level in adjacent normal tissues were used as control, housekeeping gene MRPL19 was used as the reference gene to normalize Na\textsubscript{v}1.7 expressions. c The association between Na\textsubscript{v}1.7 expression level and tumor size in the same surgical biopsies of endometrial cancer patients (r=0.78, n=20, *P*<0.05). d The tumor expression level of Na\textsubscript{v}1.7 was higher in the patients with local lymph node metastasis (2.93 ± 0.53, n=8) than those without lymph node metastasis (1.47 ± 0.71, n=12, *P*<0.05).

Fig. 3. a Kaplan-Meier analyses showing the correlation between the levels of Na\textsubscript{v}1.7 and the overall survival of patients with endometrial cancer (Na\textsubscript{v}1.7-High, n=38; Na\textsubscript{v}1.7-Low, n=21; *P*<0.05, log-rank test). b-c High Na\textsubscript{v}1.7 expression correlated with decreased survival in endometrial cancer, the 5-year survival ration (b) was decreased in Na\textsubscript{v}1.7-High group (38%) compared with Na\textsubscript{v}1.7-Low group (81%), and the 10-year survival ration (c) was decreased in Na\textsubscript{v}1.7-High group (19%) compared with Na\textsubscript{v}1.7-Low group (62%).

Fig. 4. Endometrial cancer invasion is mediated by voltage-gated sodium channel. Total number of invading cancer cells was in the absence (Control) or presence of 10 μM TTX over the time period (from 6 to 48 hours). Data were from 6 independent experiments in each group, shown were means ± SEM. *P*<0.05 versus Control.

Fig. 5. Total number of invading cells was increased in the presence of 100μM veratridine and attenuated in the presence of 100μM PF-05089771 over the time period. Data were from 6 independent experiments in each group, shown were means ± SEM. *P*<0.05 versus Control.
Discussion

This is the first study revealing the connection between voltage-gated sodium channels and endometrial cancer, examining the role of Nav1.7 sodium channel in this type of cancer.

Ion channels were well known to play significant roles in the growth and migration of cancer cells and contribute to multiple aspects and stages of cancer progress [3]. There were several ion channels implicated in endometrial cancer. The hERG K+ channels were found to be expressed with a higher frequency in primary human endometrial cancer compared to non-cancerous tissues [29]. The Ca2+ channel Ca,1.3 required for estrogen-stimulated Ca2+ influx contributed broadly to the development of endometrial cancer [30]. A recent study reported that volume-activated Cl– channel play roles in endometrial tumor invasion and migration [31]. Compared to Ca2+, K+, and Cl– channel, however, the role of voltage-gated Na+ channel in the endometrial cancer remains unknown.

The voltage-gated Na+ channel has been established to be associated with metastatic cell behavior in cancer [5, 32, 33], several Na+ channel isoforms were identified to be expressed in different cancers, these included Na,1.5 in breast and colon cancers [6, 7], Na,1.6 in cervical cancer [8], and Na,1.8 in prostate cancer [9]. In this study, we characterized Na, isoform in human endometrial cancer. We used real-time-PCR to determine transcriptional levels of sodium channel α and β subunits, and discovered that Na,1.7 α subunit in EC samples were around 25-fold higher than in NE biopsies, Na,1.7 overexpression in tumor tissue was noted in 75% cases of endometrial cancer. More importantly, the level of Na,1.7 expression was significantly associated with tumor size and survival in tumor tissues. We showed that Na,1.7 associated with endometrial cancer development, the Na,1.7 activator veratridine reduced endometrial tumor cell apoptosis and promoted cancer invasion, and inhibition of Na,1.7 by PF-05089771 increase the number of apoptotic cells and attenuated invasive potential of cancer cells.

There are several theories regarding how Na, contribute to tumor progression. One explanation is that function upregulation of Na, consequently activate the Na+/H+ exchanger (NHE) and enhance H+ efflux, thus leading to increased intracellular alkalinisation and decreased extracellular pH. In cancer cells, increased glycolytic metabolism gives rise to an excessive production of intracellular acidity; as a result, intracellular alkalinisation potentially facilitates cancer metabolism [34]. Another theory proposed that Na, could activate Na+/Ca2+ exchanger (NCX), leading to the entry of Ca2+ through the NCX, which induces Ca2+-dependent signaling to promote cancer cell proliferation and metastasis [35, 36]. In this study, Na,1.7 activator veratridine and inhibitor PF-05089771 affected endometrial cancer apoptosis and invasion, indicating that Na,1.7 have crucial roles for endometrial cancer progression. However, whether Na,1.7 activated NHE to increase H+ efflux to provide a favorable environment for endometrial tumor invasion, or induced Ca2+-dependent signaling by stimulating NCX activity to accelerate development of endometrial cancer, remain unclear; further studies are required to address these uncertainties.

In summary, the present study established a relationship between voltage-gated sodium channel protein and endometrial cancer. The Na,1.7, functionally expressed in the endometrial cancer, has strong links with clinical outcome. Its activity significantly contributes endometrial tumor progression. These findings highlight the importance of Na,1.7 in cancer development, and may provide novel insights into early detection and chemotherapeutics for endometrial cancer.

Abbreviations

Na,: voltage-gated sodium channel; Na,1.7: voltage-gated sodium channel α-subunit encoded by the SCN9A gene; EC: endometrial cancer tissues; NE: nonneoplastic endometrial samples; TTX: Tetrodotoxin.

Supplementary Material

Acknowledgments

The authors would like to thank Dr M. He (Sun Yat-Sen University, Guangzhou, Guangdong, China) for pathological work, and other members of the laboratory for insightful comments on the manuscript.

Funding

The present study was supported by the National Natural Science Foundation (No. 81502226 and 81872128) and by the Natural Science Foundation of Shandong Province (ZR2019MH040) and grant for the Key Laboratory of Higher Education Institutes of Shandong Province, China.

Author Contributions

L.H. and S.Y. conceived the project and designed experiments. J.L., H.T., W.Y. performed research; J.L., H.T., W.Y., S.Y. and L.H. analyzed the data; L.H. and J.L. wrote the paper. All authors read and edited the manuscript. All authors approved the manuscript in its current form.
Competing Interests

The authors have declared that no competing interest exists.

References